Analysis of response and acquired resistance to EGFR-TKI by multiple circulating tumor DNA with cancer-specific gene mutations
Latest Information Update: 08 Sep 2020
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 05 Sep 2018 Status changed from not yet recruiting to recruiting.
- 12 Sep 2017 New trial record